New immune therapy tested for aggressive lymphoma that Won't quit
NCT ID NCT07332507
Summary
This early-stage study is testing a new drug called teclistamab in adults whose plasmablastic lymphoma has come back or hasn't responded to previous treatments. The main goals are to find the safest dose and see what side effects occur, while also checking if the drug helps control the cancer. Teclistamab works by connecting the patient's own immune cells to the cancer cells to help destroy them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PLASMABLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.